Literature DB >> 30593515

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Amin H Nassar1,2, Renato Umeton3,4, Jaegil Kim5, Kevin Lundgren1, Lauren Harshman1, Eliezer M Van Allen1,5, Mark Preston6, Fei Dong7, Joaquim Bellmunt8, Kent W Mouw9, Toni K Choueiri1, Guru Sonpavde1, David J Kwiatkowski10,2.   

Abstract

PURPOSE: The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets. EXPERIMENTAL
DESIGN: Using targeted exome sequencing (n = 237 genes), we analyzed the mutation spectra of 82 low-grade nonmuscle-invasive bladder cancers (LG-NMIBC), 126 high-grade (HG) NMIBC, 199 muscle-invasive bladder cancers (MIBC), 10 LG-upper tract urothelial cancers (LG-UTUC), and 55 HG-UTUC.
RESULTS: FGFR3 and KDM6A mutations were significantly more common in LG-NMIBC (72% and 44%, respectively) versus other bladder subtypes. FGFR3 alterations were also enriched in LG-UTUC versus HG-UTUC tumors (80% vs. 16%). In contrast, TP53 and RB1 mutations were significantly more frequent in all 3 HG urothelial carcinoma subtypes than in LG-NIMBC (45%-58% vs. 4%; 9%-22% vs. 0; respectively). Among LG-NMIBC tumors, KDM6A mutations were more common in women than in men (71% vs. 38%). HG-NMIBC and MIBC had higher tumor mutational burden (TMB) than LG-NMIBC (P = 0.001 and P < 0.01, respectively). DNA-damage repair (DDR) alterations were associated with a higher TMB in HG-NMIBC and MIBC tumors, and these two tumor types were also enriched for an APOBEC mutational signature compared with LG-NMIBC and HG-UTUC. Alterations in FGFR3, PIK3CA, and EP300 correlated with worse overall survival in HG-UTUC and occurred concurrently.
CONCLUSIONS: Our analysis suggests that a fraction of MIBCs likely arise from precursor lesions other than LG-NMIBC. KDM6A mutations are twice as common in women with LG-NIMBC than those in men. DDR gene mutations and APOBEC mutagenesis drive mutations in HG-NMIBC and MIBC. UTUC has a distinct mutation profile from bladder cancer. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30593515     DOI: 10.1158/1078-0432.CCR-18-3147

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management.

Authors:  Aadel A Chaudhuri; Bruna Pellini; Nadja Pejovic; Pradeep S Chauhan; Peter K Harris; Jeffrey J Szymanski; Zachary L Smith; Vivek K Arora
Journal:  JCO Precis Oncol       Date:  2020-07-15

2.  RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics.

Authors:  Raie T Bekele; Amruta S Samant; Amin H Nassar; Jonathan So; Elizabeth P Garcia; Catherine R Curran; Justin H Hwang; David L Mayhew; Anwesha Nag; Aaron R Thorner; Judit Börcsök; Zsofia Sztupinszki; Chong-Xian Pan; Joaquim Bellmunt; David J Kwiatkowski; Guru P Sonpavde; Eliezer M Van Allen; Kent W Mouw
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 19.456

3.  Integrated proteogenomic characterization of urothelial carcinoma of the bladder.

Authors:  Ning Xu; Zhenmei Yao; Guoguo Shang; Dingwei Ye; Haixing Wang; Hailiang Zhang; Yuanyuan Qu; Jun Hou; Fujiang Xu; Yunzhi Wang; Zhaoyu Qin; Jiajun Zhu; Fan Zhang; Jinwen Feng; Sha Tian; Yang Liu; Jianyuan Zhao; Jianming Guo; Yingyong Hou; Chen Ding
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

Review 4.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

5.  Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.

Authors:  John L Pfail; Andrew B Katims; Parissa Alerasool; John P Sfakianos
Journal:  World J Urol       Date:  2020-10-15       Impact factor: 4.226

6.  Significance of KDM6A mutation in bladder cancer immune escape.

Authors:  Xingxing Chen; Xuehua Lin; Guofu Pang; Jian Deng; Qun Xie; Zhengrong Zhang
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

7.  Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.

Authors:  Debra T Silverman; Nathaniel Rothman; Michael Dean; Stella Koutros; Nina Rao; Lee E Moore; Michael L Nickerson; Donghyuk Lee; Bin Zhu; Larissa A Pardo; Dalsu Baris; Molly Schwenn; Alison Johnson; Kristine Jones; Montserrat Garcia-Closas; Ludmila Prokunina-Olsson
Journal:  Clin Cancer Res       Date:  2021-04-13       Impact factor: 13.801

8.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Authors:  Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope
Journal:  Cancer Discov       Date:  2020-11-02       Impact factor: 38.272

9.  Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.

Authors:  Elio Adib; Katarzyna Klonowska; Krinio Giannikou; Khanh T Do; Solida Pruitt-Thompson; Ketki Bhushan; Matthew I Milstein; Jennifer Hedglin; Katherine E Kargus; Lynette M Sholl; Junko Tsuji; David M Hyman; Anne Sisk; Geoffrey I Shapiro; Hebert A Vargas; James J Harding; Martin H Voss; Gopa Iyer; David J Kwiatkowski
Journal:  Clin Cancer Res       Date:  2021-03-16       Impact factor: 12.531

10.  Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.

Authors:  Min Yuen Teo; Jose Mauricio Mota; Karissa A Whiting; Han A Li; Samuel A Funt; Chung-Han Lee; David B Solit; Hikmat Al-Ahmadie; Matthew I Milowsky; Arjun V Balar; Eugene Pietzak; Guido Dalbagni; Bernard H Bochner; Irina Ostrovnaya; Dean F Bajorin; Jonathan E Rosenberg; Gopa Iyer
Journal:  Eur Urol       Date:  2020-08-01       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.